Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Alterations to the bone marrow microenvironment in patients with AL amyloidosis

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses alterations to the immune ecosystem and bone marrow microenvironment (BME) in patients with immunoglobin light chain (AL) amyloidosis. He emphasizes the significance of targeting the BME in AL amyloidosis for optimal treatment response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultancy: Bristol Myers Squibb, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Janssen, Karyopharm, Legend, Novartis, OncoPep, Pfizer, Takeda
Current holder of stock options: Pfizer